CURRENT
ISSUE1595
April 6, 2020
The rapid spread and severity of COVID-19 (caused
by SARS-CoV-2) have raised some questions about
use of various drugs in patients with the disease and
whether currently available drugs could be effective
in treating it. Definitive answers are lacking, but some
recommendations can be made. Updated information
on COVID-19 is available from the CDC at www.cdc.... read more...
More from issue 1595
Coming Soon
Trijardy XR - A Combination of 3 Old Drugs for Type 2 Diabetes
Topical Minocycline Foam (Amzeeq) for Acne
Drugs for Osteoarthritis
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
Recommend to Your Library
Previous Issues
March 23, 2020 (1594)
- Drugs for Irritable Bowel Syndrome
- Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
- Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
March 9, 2020 (1593)
- Peanut Allergen Powder (Palforzia)
- Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
- Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
- Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
- Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
February 24, 2020 (1592)
February 10, 2020 (1591)
- Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
- Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
- Istradefylline (Nourianz) for Parkinson's Disease
- Brolucizumab (Beovu) for Age-Related Macular Degeneration
January 27, 2020 (1590)
